CD40 and B-cell chronic lymphocytic leukemia: Our combined data indicate a novel aspect of ibrutinib efficacy, specifically its potential capacity to interrupt TLR9-induced CD40 upregulation and protein translation, which normally primes CLL cells in the LN environment for venetoclax resistance.